Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

Monika K Krzyzanowska,1,2 Jim A Julian,3 Chu-Shu Gu,7 Melanie Powis,1 Qing Li,2 Katherine Enright,6 Doris Howell,1 Craig C Earle,2,5 Sonal Gandhi,6 Sara Rask,7 Christine Brezden-Masley,3 Susan Dent,9 Leena Hajra,10 Orit Freeman,11 Silvana Spadafora,12 Caroline Hamm,13 Nadia Califaretti,14 Maureen Trudeau,10,15 Louise Bordeleau,15 James A Chiariotto,17 Christine Elser,16 Juhi Husain,19 Nicole Laferriere,20 Yasmin Rahim,21 Andrew G Robinson,22 Ted Vandenberg,23 Eva Grunfeld,24

ABSTRACT

OBJECTIVE
To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer.

DESIGN
Pragmatic, cluster randomised trial.

SETTING
20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care.

PARTICIPANTS
All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires.

INTERVENTIONS
Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle.

MAIN OUTCOME MEASURES
The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, anxiety, and quality of life.

RESULTS
Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively.

CONCLUSIONS
Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant.

TRIAL REGISTRATION
ClinicalTrials.gov NCT02485678.

Introduction
Chemotherapy has an important role in the management of many cancers but is associated with significant toxicity. As chemotherapy is mostly administered in outpatient settings, toxicities related to chemotherapy occur between visits to the cancer centre. Population based studies suggest that the use of acute care is common during chemotherapy1-3; 42% of patients receiving systemic treatment in routine practice had at least one visit to the emergency department or an admission to hospital during treatment.4 Many toxicities are predictable and can be prevented or improved with earlier intervention. Consequently, rates of use of acute care and patient outcomes could be better with effective proactive remote support between visits to the clinic.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Visits to the emergency department and admissions to hospital are common during cancer chemotherapy
These visits might be preventable with adequate support between clinic visits, but large scale studies of remote management are limited

WHAT THIS STUDY ADDS

Proactive, telephone based management of toxicities during chemotherapy did not reduce the number of visits to the emergency department or admissions to hospital
With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant

For numbered affiliations see end of the article

Correspondence to: M K Krzyzanowska monika.krzyzanowska@uhn.ca (ORCID 0000-0001-5533-7418)

Additional material is published online. To view please visit the journal online.

Cite this as: BMJ 2021;375:e066588 doi: 10.1136/bmj-2021-066588

http://dx.doi.org/10.1136/bmj-2021-066588

Accepted: 8 November 2021
Over the past decade, substantial interest has been seen in identifying approaches to support patients with cancer receiving chemotherapy between visits to the cancer centre, to minimise toxicity, improve quality of life, and reduce the use of acute care. Remote interventions, such as telephone based outreach and mobile applications or devices, have shown promise in early phase or proof of concept individually randomised studies. Although large scale evaluations are currently in progress, data on the effectiveness and scalability of these types of interventions at a system level are limited. In our previous single arm two institution study of a proactive, telephone based outreach strategy which focused on the management of toxicity by trained oncology nurses in patients undergoing adjuvant chemotherapy for breast cancer, we showed that the intervention was feasible, acceptable to patients and providers, and associated with fewer visits to the emergency department compared with historical controls. Here, we report the effectiveness of remote proactive management of toxicities related to chemotherapy in patients with early stage breast cancer receiving chemotherapy, in a multicentre, pragmatic, cluster randomised trial where the primary outcome was evaluated with existing administrative healthcare data. We also conducted a study of validated questionnaires in a subset of patients to evaluate the effect of the intervention on patient reported outcomes.

Methods

Study design

We conducted a pragmatic, cluster randomised trial to evaluate the effect of proactive, nurse led, telephone based management of symptoms on the cluster level number of visits to the emergency department or admissions to hospital per patient; the full trial protocol has been published previously. Briefly, 20 cancer centres in Ontario, Canada, were randomly allocated to proactive remote management (intervention, n=10) or routine care (control, n=10), grouped by the size of the centre (large, medium, or small, based on historical numbers of patients with breast cancer). Participants had early stage (stages I-III) breast cancer and were starting adjuvant or neoadjuvant chemotherapy at participating institutions during the intervention period. Excluded were patients receiving an investigational drug or treated exclusively with hormonal or targeted treatments.

Ethical considerations

The intervention was introduced into the centres as a process change according to quality improvement principles, and therefore individual written informed consent was waived. Informed consent was also waived for control centres providing their local standard of care. The subset of patients participating in the patient reported outcomes sub-study were asked to provide individual written informed consent to participate and for linkage of their patient reported outcome data to provincial administrative data.

Intervention arm

The cluster randomisation was performed at the Ontario Clinical Oncology Group, Hamilton, Ontario, with population based administrative healthcare data to determine historical patient volumes, number of visits to acute care facilities, Charlson comorbidity index, urban versus rural geographical location, stage of cancer, chemotherapy regimen, type of facility, and centre surveys to determine the nursing model and the proportion of non-English speaking patients. Centres randomised to the intervention arm offered the proactive telephone symptom management programme to all eligible patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer during the enrolment period.

Participants in the intervention arm received a copy of the Symptom Self-Management Booklet-patient edition (supplementary file 1) and two structured follow-up calls during each cycle of chemotherapy: 24-72 hours and 8-10 days after the start of each cycle (supplementary figure 1). During the calls, symptoms were assessed by locally designated oncology nurses with a standardised questionnaire (supplementary file 2), looking at nine common toxicities related to chemotherapy: nausea, vomiting, mouth and throat sores, pain, aching joints and aching muscles, loose and watery stools, shivering or shaking chills, constipation, and fatigue or tiredness. Standardised guidance of the management of symptoms was provided by the Symptom Self-Management Booklet-provider edition (supplementary file 3) and the telephone follow-up script (supplementary file 4). The care team made unscheduled calls to follow-up on symptoms or to provide more support at their discretion.

Control arm

Participants in the control centres received standard care according to their institution. Typically, standard care involved baseline patient education on chemotherapy and common side effects, and advice to call the cancer centre about symptoms or concerns related to the treatment between visits to the clinic.

Primary outcome

The primary outcome was the cluster level mean number of visits to the emergency department or admissions to hospital per patient during the at-risk period, defined as the chemotherapy treatment period from the first day of the first cycle of chemotherapy to 30 days after the last chemotherapy treatment. The primary outcome was measured with administrative healthcare data from Ontario. Ontario has a single payer universal healthcare system with a comprehensive population based cancer registry capturing diagnostic and demographic information on about 98% of patients. All patients with breast cancer at the participating centres who started adjuvant or neoadjuvant chemotherapy during the intervention period were identified from the provincial activity level reporting database, which includes information on drugs received, dates of...
treatment, and the institution where the treatment was given. The Ontario Cancer Registry was used to confirm that the patient had early stage breast cancer. The National Ambulatory Care Reporting System and Canadian Institutes for Health Information Discharge Abstract Database are comprehensive databases that capture all visits to the emergency department and admissions to hospital, respectively, at any hospital in Ontario; details of this methodology have been described previously. Briefly, all unique visits to the emergency department and admissions to hospital during the at-risk period were identified and added for each patient. Visits to the emergency department that led to admission to hospital were counted as one acute care episode.

Secondary outcomes
Implementation fidelity (the degree to which an intervention is delivered as intended) was assessed based on the core elements of Carrol et al. Adherence was defined as completion of 80% of the expected telephone calls on managing toxicities related to chemotherapy (patient reached and counselling provided) within the call window specified by the protocol. Penetration was defined as the proportion of patients who received the intervention at the 10 intervention sites out of those eligible, which was determined from the administrative healthcare data. After a run-in period of one month following the start of the study, the centres were instructed to approach consecutive eligible patient to participate in the patient reported outcomes study until the recruitment target of at least 25 patients per centre (500 overall) was reached. Participants completed the validated patient reported outcome questionnaires before the start of the first (visit 1, baseline) and second (visit 2) cycles of chemotherapy, and within 60 days of the end of treatment (visit 3). Participants who received a chemotherapy regimen where they switched to a different drug part way through their treatment (usually a taxane was added) completed another patient reported outcome questionnaire before the start of the second cycle of the second drug (visit 2a). The severity of the toxicities related to chemotherapy was measured and scored with the National Cancer Institute patient reported outcomes version of the common terminology criteria for adverse events (NCI PRO-CTCAE) self-report tool. Self-efficacy or confidence in managing symptoms was measured with the Stanford self-management self-efficacy scale, and general quality of life by the EQ-5D-3L (three level version of the European quality-of-life five dimension instrument). The patient health questionnaire and generalised anxiety disorder scales measured major depression and anxiety, respectively. Physical, social, and family wellbeing were measured with the functional assessment of cancer therapy for patients with breast cancer (FACT-B) scales. Coordination and continuity of care was evaluated with the adapted Picker survey.

Statistical analysis
For the primary outcome, we conducted two different simulation approaches to determine sample size: (1) assuming an over disperse Poisson model (negative binomial distribution) for the number of visits to the emergency department or admissions to hospital, and with summary data from an a prior population based cohort of patients with breast cancer, we selected the top 25 cancer treatment centres in Ontario by patient volume to maintain estimate stability; and (2) with the actual data from the cohort and randomly allocating the 20 largest centres equally to a control or treatment arm within five groups, based on the number of patients with breast cancer treated at each centre. With the first model based approach, we applied a design effect to the number calculated assuming independence. The intraclass correlation for the top 25 cohort was estimated at 0.028. In the second actual data approach, we reduced the observed visits by a fixed prespecified percentage, ranging from 20% to 40%. Both approaches resulted in similar estimates. About 73 women per centre (total sample size=1460) from 20 centres were needed to achieve 80% power to detect a 33% reduction in the number of visits to the emergency department or admissions to hospital, with a one sided $\alpha$ value of 2.5%. For the patient reported outcomes study, at least 25 participants per centre (total sample size=500) were needed for 80% power (one sided $\alpha$ value of 2.5%) to detect a treatment effect size of 0.35 standard deviations, with adjustment for clustering (intraclass correlation=0.028) and an allowance of 3% for non-compliance.

We used descriptive statistics to summarise the characteristics of the full study cohort and the patient reported outcomes study cohort. Aggregated diagnosis group was derived from the Johns Hopkins Adjusted Clinical Groups System as a validated measure of the complexity of comorbidities and the consumption of resources. The effect of the intervention on the unweighted centre level mean number of visits to the emergency department or admissions to hospital per patient was calculated for both the size of the centre (small, medium, or large) and overall, for the intervention and control arms, and compared using the t scores (evaluated with only the 2890 acceptable permutations of the 20 centres after applying covariate based restrictions) and the permutation test. Confidence intervals were calculated by bootstrapping. Supplementary file 5 gives details of the analysis, including a supportive analysis with patient level data and a sensitivity analysis.

Patient reported outcomes (secondary outcomes) were measured at the patient level. The worst grade (grade 3) toxicities reported after baseline, based on the NCI PRO-CTCAE, were summarised for the intervention and control arms and compared with a mixed effects logistic model adjusting for fixed effects (baseline toxicity score, intervention, and size of the centre) and centre as a random effect. Correlations for different patients within the same cluster were taken
into account in the model, and a general unstructured covariance model was assumed. The effect of the intervention on the quality of life patient reported outcome measures was evaluated with linear mixed models for repeated measures (fixed effects included the baseline quality of life score, intervention, visit, intervention-by-visit interaction, and size of the centre; random effects were centres, with an unstructured covariance matrix for visits and the clustering of the individuals within centres). All analyses were conducted with SAS 9.4 and R 3.5 on the Institute for Clinical Evaluative Sciences data and analytic virtual environment secure server.

**Patient and public involvement**

At the time that this study was first conceptualised, including patients as research team members was not usual practice in Canada and hence patients were not formally involved in the research process. However, we did seek consultation on the study concept with patients at multiple time points throughout the research process. The proposal was presented at Cancer Care Ontario, the provincial body overseeing cancer care, for feedback and engagement, with patient partner involvement on several occasions. Also, our previous pilot study involved the collection of patient satisfaction measures and extensive end-of-study patient interviews on the intervention content and delivery, which informed the design of this trial.

**Results**

**Cohort description**

During the enrolment period from February 2016 to November 2017, 2158 patients started adjuvant or neoadjuvant chemotherapy for early stage breast cancer at the 20 participating institutions (fig 1). Baseline characteristics (table 1) were similar in the intervention (n=944) and control arms (n=1214). Median age was 55, and most participants had stage 2 disease. The most commonly used regimens were AC-paclitaxel (doxorubicin (Adriamycin) and cyclophosphamide, followed by paclitaxel) and FEC-docetaxel (5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel). Baseline characteristics for the 580 patients (27% of the main cohort) who participated in the patient reported outcomes study were similar to those of the main cohort (table 1).

**Intervention delivery characteristics**

The number of participants who received the intervention varied by cancer centre (range 44-141 patients; supplementary table 1). The overall intervention penetration at centres randomised to the intervention arm was 68% (range over 10 centres 50-86%). Of the 7940 expected proactive calls, 78% were completed (range 60-95%), of which 84% were completed within the time window (range 68-97%). We found no trend between centre size and the proportion of calls delivered; 347 unscheduled calls were made at the discretion of the intervention nurses over the
course of delivering the intervention, and the number of completed extra calls varied by centre (range 1-115).

**Effect of intervention on visits to the emergency department and admissions to hospital**

Overall, 47% (1014 of 2158 patients) of patients had at least one visit to the emergency department or admission to hospital during treatment. Figure 2 shows the distribution of visits to the emergency department or admissions to hospital by the size of the centre (large, medium, or small) and overall (supplementary table 2 shows individual centre data). Large control centres and small intervention centres had fewer visits to the emergency department or admissions to hospital (supplementary table 3). Based on the centre level mean number of visits to the emergency department or admissions to hospital, we found no significant difference between the intervention (0.91, standard deviation 0.28) and control (0.94, 0.40) groups, with a mean absolute difference of −0.024 (95% confidence interval −0.064 to 0.016).

**Table 1 | Characteristics of full cohort and patient reported outcomes cohort. Data are number (%) of participants unless stated otherwise**

| Characteristic          | Full cohort (n=2158) | Patient reported outcomes cohort (n=580) |
|-------------------------|----------------------|-----------------------------------------|
| Age (years)*            |                      |                                         |
| <60                     | 86 (9)               | 31 (11)                                 |
| 40-44                   | 84 (9)               | 26 (9)                                  |
| 45-49                   | 117 (12)             | 42 (15)                                 |
| 50-54                   | 171 (18)             | 44 (16)                                 |
| 55-59                   | 128 (14)             | 38 (13)                                 |
| 60-64                   | 135 (14)             | 45 (16)                                 |
| 65-69                   | 117 (12)             | 39 (14)                                 |
| 70-74                   | 61 (6)               | 12 (5)                                  |
| ≥75                     | 45 (5)               | 6 (2)                                   |
| Stage                   |                      |                                         |
| 1                       | 215 (23)             | 63 (22)                                 |
| II                       | 264 (28)             | 82 (29)                                 |
| IIB                     | 216 (23)             | 67 (24)                                 |
| IIIA                    | 139 (15)             | 44 (16)                                 |
| IIBB                    | 44 (5)               | 9 (3)                                   |
| IIIC                    | 42 (4)               | 9 (3)                                   |
| IV                      | ≥6 (NR)              | 16 (NR)                                 |
| Unknown                 | 22 (2)               | 6 (NR)                                  |
| Chemotherapy Regimen:   |                      |                                         |
| AC-P                    | 417 (44)             | 118 (42)                                |
| FEC-D                   | 234 (25)             | 80 (28)                                 |
| TC                      | 201 (21)             | 58 (20)                                 |
| AC-Doc                  | 8 (1)                | 6 (NR)                                  |
| Other                   | 84 (9)               | 25 (9)                                  |
| Class:†                 |                      |                                         |
| Anthracycline           | 664 (70)             | 202 (71)                                |
| Doxorubicin             | 478 (51)             | 156 (55)                                |
| Paclitaxel              | 456 (48)             | 124 (44)                                |
| Charlsion score         |                      |                                         |
| 0                       | 226 (24)             | 60 (21)                                 |
| 1                       | 35 (4)               | 10 (4)                                  |
| ≥2                     | 20 (2)               | 6 (NR)                                  |
| Income group            |                      |                                         |
| 1                       | 148 (16)             | 40 (14)                                 |
| 2                       | 184 (19)             | 54 (19)                                 |
| 3                       | 191 (20)             | 58 (20)                                 |
| 4                       | 186 (20)             | 61 (22)                                 |
| 5                       | 234 (25)             | 70 (25)                                 |
| ADG total               |                      |                                         |
| 0-4                     | 171 (18)             | 50 (18)                                 |
| 5-9                     | 527 (56)             | 160 (56)                                |
| ≥10                     | 246 (26)             | 73 (26)                                 |
| Mean (range)            | 7.6 (0-20)           | 7.1 (0-23)                              |
| Rural                   |                      |                                         |
| Yes                     | 79 (8)               | 27 (10)                                 |
| No                      | 864 (92)             | 256 (90)                                |

*AC-P=doxorubicin (Adriamycin), cyclophosphamide, paclitaxel; FEC-D=fluorouracil, epirubicin, cyclophosphamide, docetaxel; TC=docetaxel, cyclophosphamide; AC-Doc=doxorubicin (Adriamycin), cyclophosphamide, docetaxel; ADG=aggregated diagnostic group; NR=not reported because counts were <6 (Institute for Clinical Evaluative Sciences where analyses were performed does not allow reporting of cells with <6 patients).

*Median age is 55.7 (estimated from grouped data).

†Patients might fit into more than one category.
The intraclass correlation for the primary outcome was 0.018 versus 0.028, which was used in our sample size calculations. A covariate adjusted supportive analysis and a sensitivity analysis did not affect the results (supplementary file 5). Also, we found no cluster level differences between the intervention and control arms for visits to the emergency department alone (mean absolute difference −0.010, 95% confidence interval −0.216 to 0.145, P=0.92) or admissions to hospital (−0.014, −0.064 to 0.035, P=0.67). Intervention penetration had no effect on the primary outcome.

### Effect on patient reported outcomes

Twenty two participants in the patient reported outcomes study did not complete a questionnaire (five in the intervention arm and 14 in the control arm). At least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm (P=0.0053, table 3). Substantial differences were observed between the intervention and control arms in the proportion of patients experiencing grade 3 fatigue (58 of 278 patients (21%) vs 90 of 283 (32%)), aching joints (61 (22%) vs 84 (30%) patients), and aching muscles (53 (19%) vs 77 (27%) patients). Supplementary table 4 gives a more detailed analysis of the toxicity grade during follow-up. We found no effect of the intervention on anxiety (generalised anxiety disorder 7) or depression (patient health questionnaire 9) (table 4). We also found no improvement in self-efficacy (Stanford self-management self-efficacy scale) or coordination of care (adapted Picker survey) in patients receiving the intervention. During the at-risk period, patients in the intervention group had a smaller decline from baseline for the functional assessment of cancer therapy (FACT) trial outcome index (−6.1 vs −9.0, difference 2.9, 95% confidence interval 0.8 to 5.0) and FACT physical wellbeing (−3.0 vs −4.6, 1.6, 0.7 to 2.5).

### Discussion

#### Principal findings

Over the past decade, there has been substantial interest in identifying effective approaches to support patients with cancer remotely during chemotherapy, to minimise toxicity, improve quality of life, and reduce the use of acute care facilities. In our trial, we found that despite a high overall rate of use of acute care in this patient population (47% of patients had at least one visit to the emergency department or admission to hospital during treatment), proactive telephone management of toxicities related to chemotherapy of curative intent did not result in a decrease in the number of visits to the emergency department or admissions to hospital between the intervention and control centres. Failure to detect a difference could be because of suboptimal penetration (overall 68%, range 50-86%) or low intervention fidelity (78% of calls were completed, centre range 60-95%), or both, diluting any potential observable effect, although we did not see a strong correlation between penetration and visits to the emergency department or admissions to hospital. Unfortunately, complex interventions that show early promise but then fail to translate to substantial differences in outcomes after large scale implementation is not unusual.27 Furthermore, proactive support might have directed patients to the emergency department who would otherwise not have sought care because some of the nursing algorithms advise patients to go to the emergency department if...
Comparison with other studies

Our intervention was associated with a lower proportion of patients with grade 3 toxicities ($P=0.05$), especially fatigue ($P=0.009$), aching joints ($P=0.003$), and aching muscles ($P=0.004$), and significant findings for quality of life outcomes that did not fully meet the criteria for a clinically important difference.32 These findings are similar to previous studies, which showed that proactive remote monitoring of symptoms during cancer treatment is associated with a positive effect on symptoms and quality of life8 33 34 and suggests that the effect on symptom burden might be scalable beyond individually randomised trials. In contrast with physical symptoms, our intervention was not associated with improvements in other patient reported outcomes, such as self-efficacy, anxiety, or depression. Lack of effect on self-efficacy could be because of high baseline scores and a possible ceiling effect, and a focus on the management of symptoms rather than teaching self-management behaviours. A recent single centre trial of remote electronic monitoring coupled with self-management training during chemotherapy reported improved self-efficacy in the intervention arm.35 Lack of effect on anxiety or depression might be because of the content of the calls, which focused on physical rather than emotional symptoms.

Strengths and limitations

This study had several unique design aspects: cluster randomisation, introduction of the intervention as a process change according to quality improvement principles at each intervention centre, a pragmatic approach that mimicked implementation in routine practice, and the use of existing population based administrative healthcare data to evaluate the primary outcome. Substantial interest in the use of routinely collected healthcare data to improve clinical trials by decreasing costs and burden has been reported,27 although a recent systematic review suggested that such trials might show smaller treatment effects than traditional trials.35 We showed that use of routinely collected administrative data to evaluate trial outcomes is feasible. Use of administrative data in our study facilitated the recruitment of smaller community centres into our trial; extensive collection of primary data could have been a barrier to participation for these smaller centres. Furthermore, for outcomes such as use of healthcare services, administrative data might be more accurate than patients’ own reports.

The study had some limitations. We conducted a covariate constrained randomisation to minimise imbalance between the intervention and control arms.
Interaction terms were found to be significant (P<0.05). Correlations for different patients in the same cluster and for different visits from the same patient have also been taken into account in the model.

With general linear mixed modelling, the predictors are considered to have a fixed or random effect. Fixed effects include baseline score, intervention, visit, intervention-visit interaction, and size of centre group; centre is a random effect.

Score ranges for instruments: FACT-B total score (0–148); EQ-5D-3L VAS (0–100); Picker (adapted) (0–100); Stanford (1–10); GAD-7 (0–21); PHQ-9 (0–27).

Table 4 | Patient reported quality of life outcomes linear mixed model analysis for change from baseline

| Scale* | Visit change | Intervention estimate (SE) | Control estimate (SE) | Difference estimate (95% CI)† | Overall effect (P value)‡ |
|--------|--------------|---------------------------|-----------------------|-----------------------------|-------------------------|
| Trial outcome index | V2–V1 | −2.4 (0.7) | −4.9 (0.6) | 2.5 (0.7 to 4.3) | 0.001 0.004 |
| | V2a–V1 | −7.7 (0.8) | −9.6 (0.8) | 2.0 (−0.2 to 4.2) | 0.15 0.15 |
| | V3–V1 | −6.1 (0.8) | −9.0 (0.8) | 2.9 (0.8 to 5.0) | 0.001 0.001 |
| Physical wellbeing | V2–V1 | −0.7 (0.3) | −3.4 (0.3) | 2.7 (1.0 to 3.9) | 0.01 0.01 |
| | V2a–V1 | −6.3 (0.4) | −5.3 (0.3) | 1.0 (0.0 to 2.0) | 0.001 0.001 |
| | V3–V1 | −3.0 (0.3) | −4.6 (0.3) | 1.6 (0.7 to 2.5) | 0.05 0.05 |
| Social wellbeing | V2–V1 | 0.0 (0.2) | −0.3 (0.2) | 0.3 (0.3 to 0.9) | 0.001 0.51 |
| | V2a–V1 | −0.5 (0.3) | −0.6 (0.2) | 0.1 (0.0 to 0.8) | 0.001 0.51 |
| | V3–V1 | −0.8 (0.2) | −0.9 (0.2) | 0.1 (0.0 to 0.8) | 0.001 0.51 |
| Emotional wellbeing | V2–V1 | 1.4 (0.2) | 1.4 (0.2) | 0.0 (0.4 to 0.4) | 0.95 0.89 |
| | V2a–V1 | 1.2 (0.2) | 1.6 (0.2) | −0.4 (0.9 to 0.2) | 0.95 0.89 |
| | V3–V1 | 1.6 (0.2) | 1.3 (0.2) | 0.3 (0.2 to 0.8) | 0.95 0.89 |
| Functional wellbeing | V2–V1 | −0.6 (0.3) | −1.5 (0.3) | 0.8 (0.1 to 1.6) | 0.001 0.15 |
| | V2a–V1 | −2.8 (0.3) | −2.9 (0.3) | 0.1 (0.8 to 1.0) | 0.001 0.15 |
| | V3–V1 | −2.0 (0.3) | −2.5 (0.3) | 0.5 (−0.3 to 1.4) | 0.001 0.15 |
| EQ-5D-3L VAS | V2–V1 | 3.3 (0.8) | −0.8 (0.8) | 2.1 (0.1 to 4.2) | 0.001 0.031 |
| | V2a–V1 | −2.4 (1.1) | −5.8 (1.1) | 3.4 (0.4 to 6.4) | 0.001 0.031 |
| | V3–V1 | −3.6 (1.0) | −4.7 (1.0) | 1.1 (−1.6 to 3.8) | 0.001 0.031 |
| Stanford | V2–V1 | 0.3 (0.1) | 0.3 (0.1) | 0.0 (0.3 to 0.3) | 0.009 0.57 |
| | V2a–V1 | 0.2 (0.1) | −0.1 (0.1) | 0.2 (0.1 to 0.3) | 0.009 0.57 |
| | V3–V1 | 0.3 (0.1) | 0.3 (0.1) | 0.0 (0.3 to 0.3) | 0.009 0.57 |
| Picker (adapted) | V2–V1 | 6.0 (1.4) | 4.0 (1.4) | 2.0 (−2.0 to 5.9) | 0.093 0.67 |
| | V2a–V1 | 7.0 (1.8) | 7.1 (1.7) | −0.1 (−5.1 to 4.9) | 0.093 0.67 |
| | V3–V1 | 4.6 (1.6) | 4.2 (1.5) | 0.4 (−3.9 to 4.7) | 0.093 0.67 |
| GAD-7 | V2–V1 | −2.1 (0.2) | −2.1 (0.2) | 0.0 (0.5 to 0.6) | 0.91 0.59 |
| | V2a–V1 | −2.4 (0.2) | −2.0 (0.2) | −0.4 (−1.2 to 0.3) | 0.91 0.59 |
| | V3–V1 | −2.1 (0.2) | −2.2 (0.2) | 0.1 (−0.6 to 0.7) | 0.91 0.59 |
| PHQ-9 | V2–V1 | 0.3 (0.2) | 0.7 (0.2) | −0.4 (−1.0 to 0.2) | 0.001 0.001 |
| | V2a–V1 | 1.2 (0.3) | 1.7 (0.3) | −0.5 (−1.2 to 0.3) | 0.001 0.001 |
| | V3–V1 | 0.6 (0.2) | 1.0 (0.2) | −0.4 (−1.1 to 0.2) | 0.001 0.001 |

SE=standard error; V1=baseline; V2=before start of second cycle; V2a=before start of second cycle of a taxane (if they switched regimens); V3=within 60 days of the end of chemotherapy; PHQ-9=patient health questionnaire 9; EQ-5D-3L VAS=three level version of the European quality of life five dimension visual analogue scale; GAD-7=generalised anxiety disorder 7; Stanford=Stanford self-management self-efficacy scale.

With general linear mixed modelling, the predictors are considered to have a fixed or random effect. Fixed effects include baseline score, intervention, visit, intervention-visit interaction, and size of centre group; centre is a random effect. Correlations for different patients in the same cluster and for different visits from the same patient have also been taken into account in the model. No interaction terms were found to be significant (P>0.05).

Based on the primary outcome, the patient reported outcome endpoints were prespecified as secondary outcomes, but the patient reported outcomes study did not account for multiple comparisons and therefore we chose the conservative approach and considered them exploratory. Also, the patient reported outcome questionnaires were completed by 580 patients, a subset of the total study population (27%), who might not have been representative of the full cohort. The study protocol specified an interval between accrual for the study (February 2016 to November 2017) and reporting of the findings, to allow for completion of the toxicity observation window and for the updated administrative data holdings covering the study period to become available from the Institute for Clinical Evaluative Sciences (updated annually for some databases). Administrative data lack the clinical contextual information required to understand the appropriateness of care or potential drivers of observed outcomes, such as patient preferences or unmeasured confounders. Also, the study was conducted in Ontario, Canada, which has a universal single payer system, so administrative records capture the complete care episode consistently and completely for patients with cancer. Issues might arise operating a similar methodology in multipayer systems. Lastly, extra unscheduled calls were made in the intervention arm, which might increase the resources required to deliver the intervention and should be considered in the design of future studies.

Conclusions

Remote, proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or admissions to hospital in this multicentre cluster randomised trial. Given the high level of acceptability of the intervention by patients and providers, and with a growing body of evidence from other studies showing the benefits of remote monitoring during chemotherapy, future studies of proactive remote management should focus on pragmatic large scale implementation in routine care settings. Although implementation issues with evaluations of large scale programmes persist, with the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote support of patients during cancer treatment is particularly relevant, including telephone based...
interventions, as this remains an important method for delivery of virtual care. Because of the resource implications of large scale implementation of such programmes, provision of proactive monitoring during cancer treatment to high risk patients (those receiving certain regimens) or high risk situations (at the beginning of chemotherapy or in advanced disease), might facilitate widespread adoption and should be prioritised for study.

AUTHOR AFFILIATIONS

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
3Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada
4Trillium Health Partners, Credit Valley Hospital, Mississauga, ON, Canada
5Ontario Institute for Cancer Research, Toronto, ON, Canada
6Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
7Simcoe Muskoka Regional Cancer Program, Royal Victoria Hospital, Barrie, ON, Canada
8St Michael’s Hospital, Unity Health, Toronto, ON, Canada
9Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
10Markham Stouffville Hospital, Markham, ON, Canada
11Durham Regional Cancer Centre, Oshawa, ON, Canada
12Algoma District Cancer Programme, Sault Area Hospital, Sault Ste Marie, ON, Canada
13Windsor Regional Hospital, Windsor, ON, Canada
14Grand River Hospital’s Regional Cancer Centre, Kitchener, ON, Canada
15Juravinski Cancer Centre, Hamilton, ON, Canada
16Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
17Scarborough Health Network, Toronto, ON, Canada
18Mount Sinai Hospital, Toronto, ON, Canada
19Brampton Civic Hospital, Brampton, ON, Canada
20Regional Cancer Centre Northwest, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada
21Stronach Regional Cancer Centre, Newmarket, ON, Canada
22Kingston General Hospital, Kingston, ON, Canada
23Lawson Health Research Institute, London, ON, Canada
24Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada

Previous presentation: Findings were presented virtually at the European Society for Medical Oncology annual congress, September 2020.

Contributors: Authors contributed to the concept and design (MKK, JA, MP, KE, DH, CCE, MNL, and EG), acquisition of the data (KE, SG, SR, CB-M, SD, LH, OF, SS, CH, NC, MT, MNL, EA, LB, JAC, CE, JH, NL, YR, AGHR, and TV), analysis and interpretation (MKK, JA, C50, MP, QL, MNL, and EG), drafting and revision (all authors), final approval (all authors), and agreement to be accountable (all authors). The guarantor (MKK) accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This project was funded through an Ontario Institute for Cancer Research (OICR) Health Services Research programme grant. This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long term Care (MOHLTC).

The opinions, results, and conclusions reported in this paper are those of the authors and are independent of the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interests/ and declare: support from the Ontario Institute for Cancer Research (OICR) for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, CCE and EG hold appointments at the OICR Health Services Research Programme; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The study was approved by the Ontario Cancer Research Ethics Board, a centralised ethics board used by 18 of the participating cancer centres (15–041), the Sault Area Hospital Research Ethics Board, and the Rouge Valley Health System Research Ethics Board.

Data sharing: Relevant anonymised patient level data available on reasonable request.

The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: How best to disseminate the trial findings was studied through interviews with key stakeholder groups, such as physicians, nurses, and management, after completion of the trial. This also involved studying potential facilitators and barriers to implementation, should the results warrant. We found wide support for the trial from most stakeholders. All stakeholders identify evidence of effectiveness as a key facilitating factor. However, as the primary outcome of the trial was qualitative, we will work in consultation with the quality improvement programme at the Ontario provincial cancer agency to agree key messaging to stakeholders. The results will be presented in a debriefing session with all participating cancer centres. Nationally, the results will be presented at the Canadian Cancer Research Conference. Internationally, the results have already been presented virtually at the European Society for Medical Oncology annual congress, September 2020.

Provenance and peer review: Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

1 Enright K, Grunfeld E, Yun L, et al. Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. J Clin Oncol Pract 2015;11:126-32. doi: 10.1200/JOP.2014.001073
2 Pittman NM, Hopman WM, Mates M. Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer. J Oncol Pract 2015;11:120-5. doi: 10.1200/JOP.2014.000257
3 Eskander A, Krzyzanowska MK, Fischer HD, et al. Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis. Oral Oncol 2018;83:107-14. doi: 10.1016/j.oraloncology.2018.06.011
4 Princer RM, Powsis M, Zer A, Atenafu EG, Krzyzanowska MK. Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: A systematic review and meta-analysis. Eur J Cancer Care (Engl) 2019;28:e12909. doi: 10.1111/ecc.12909
5 Mooney KH, Beck SL, Friedman RH, Farzangar R. Telephone-linked care for cancer symptom monitoring: a pilot study. Cancer Pract 2002;10:147-54. doi: 10.1046/j.1537-3394.2002.00306.x
6 Mooney KH, Beck SL, Friedman RH, Farzangar R, Wong B. Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers’ use of the information: a randomized controlled clinical trial. Support Care Cancer 2014;22:2343-50. doi: 10.1007/s00520-014-2216-1
7 Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 2016;34:557-65. doi: 10.1200/JCO.2015.63.0830
8 Kearney N, McCain L, Nonne J, et al. Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Support Care Cancer 2009;17:437-44. doi: 10.1007/s00520-008-0515-0
Maguire R, Fox PA, McCann L, et al. The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (AsyMS) remote technology for patients with cancer. BMJ Open 2017;7:e015016. doi: 10.1136/bmjopen-2016-015016

Basch E. Electronic Patient Reporting of Symptoms During Cancer Treatment (PRO-TECT). US National Library of Medicine: ClinicalTrials.gov. 2017. https://clinicaltrials.gov/ct2/show/NCT03249090.

Krzyanowska MK, MacKay C, Han H, et al. Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer. Pilot Feasibility Stud 2019;5:39. doi: 10.1186/s12885-019-0404-y

Kim SY, Miller FG. Informed consent for pragmatic trials—the integrated consent model. N Engl J Med 2014;370:769-72. doi: 10.1056/NEJMe1312508

Clarke EA, Maret LD, Kreiger N. Cancer registration in Ontario: a computer approach. JRC Sci Publ 1991;95:246-7.

Carroll C, Patterson M, Wood S, Booth A, Rick J, Balais S. A conceptual framework for implementation fidelity. Implement Sci 2007;2:40. doi: 10.1186/1748-5908-2:40

Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014;106:1244-5. doi: 10.1093/jnci/dju244

Bennett AV, Durec AC, Mitchell SA, et al, National Cancer Institute PRO-CTCAE Study Group. Mode equivalence and acceptability of tablet computer-interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016;14:24. doi: 10.1186/s12955-016-0426-6

Basch E, Becker C, Rocka LJ, et al. Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials 2021;18:104-14. doi: 10.1177/1740774520975120

Ritter PL, Long K. The English and Spanish Self-Efficacy to Manage Chronic Disease Scale measures were validated using multiple studies. J Clin Epidemiol 2016;67:1265-73. doi: 10.1016/j.jclinepi.2016.04.009

EuroQol Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. doi: 10.1016/0168-8510(90)90421-9

Smith AB, Rady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. Psychooncology 2009;18:195-9. doi: 10.1002/pon.1423

Lowe B, Decker D, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008;46:266-74. doi: 10.1097/MED.0b013e181609093

Brady NJ, Cella DF, Mo F, et al. Reliability and Validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974-86. doi: 10.1200/JCO.1997.15.3.974

National Research Corporation. Ontario Hospital Association N.K.C. Development and Validation of the Picker Ambulatory Oncology Survey Instrument in Canada. National Research Corporation, 2003.

Husain A, Barbera L, Howell D, Moineddin R, Bejzak A, Sussman J. Advanced lung cancer patients’ experience with continuity of care and supportive care needs. Support Care Cancer 2013;21:1351-8. doi: 10.1007/s00520-012-1673-7

Johns Hopkins. ACG System White Paper. https://www.johnshopkinsinstruments.com/wp-content/uploads/2014/04/ACG-White-Paper-General-Dec-2012.pdf

Bhansali S, Gill TM, Reuben DB, et al, STRIDE Trial Investigators. A randomized trial of a multifactorial strategy to prevent serious falls injuries. N Engl J Med 2020;383:129-40. doi: 10.1056/NEJMc2002183

Barbera L, Moody L. A decade in review: cancer care Ontario’s approach to symptom assessment and management. Med Care 2019;57(Suppl 1):S80-4. doi: 10.1097/ MLR.0000000000001084

Ontario C. Connecting Care 24/7. Cancer Care Ontario, 2019. https://www.cancercareonto.ca/en/blog/Connecting%20care%20%20-%2024/7

Ontario C. Quality-Person-Centred Systematic Treatment in Ontario. Cancer Care Ontario, 2014. https://www. cancercareonto.ca/sites/cccancercare/files/assets/CCOSystematicTreatmentPlan.pdf.

Hamilton Health Science. Rapid Evaluation and Symptom Support Cancer Unit (Resscu). Ontario: Hamilton Health Science, 2019. https://www.hamiltonhealthsciences.ca/en/areas-of-care/cancer-care/cancer-services/resscu/

Jayadevappa R, Cook R, Chhatre S. Minimal important difference to infer changes in health-related quality of life—a systematic review. J Clinical Epidemiol 2017;89:188-98. doi: 10.1016/j. jclinepi.2017.06.009

Beck SL, Eaton LH, Echeverria C, Mooney KH. SymptomCare@Home: Developing an integrated symptom monitoring and management system for outpatient patients receiving chemotherapy. Comput Inform Nurs 2017;35:520-9. doi: 10.1097/CIN.0000000000000364

Absalom K, Warrington L, Hudson E, et al. Phase III randomized controlled trial of eRapid: eHealth intervention during chemotherapy. J Clin Oncol 2021;39:734-47. doi: 10.1200/JCO.20.20201

McCord KA, Ewah L, Agarwal A, et al. Treatment effects in randomized trials using routinely collected data for outcome assessment: a simulation of randomized trials: meta-research study. BMJ 2021;372:n450. doi: 10.1136/bmj.n450

Enright KA, Krzyanowska MK. Benefits and pitfalls of using administrative data to study hospitalization patterns in patients with cancer treated with chemotherapy. J Oncol Pract 2016;12:140-1. doi: 10.1200/JOP.2015.008482

Goel V, Williams J, Anderson GM, Blackstein-Hirsch P, Fooks C, Naylor CD, eds. A summary of studies on the quality of healthcare administrative databases in Canada. Patterns of Healthcare in Ontario: The ICES Practice Atlas. Canadian Medical Association, 1996.

O’Brien MA, Cornacchi S, Mukauwaza T, et al. Implementation of an ambulatory toxicity management (AToM) intervention for patients with breast cancer. Canadian Cancer Research Conference, November 3-5, 2019, Ottawa, ON.

Berlin A, Lovas M, Truong T, et al. Implementation and outcomes of virtual care across a tertiary cancer center during COVID-19. JAMA Oncol 2021;7:597-602. doi: 10.1001/jamaoncol.2020.6982

Grant RC, Moineddin R, Yao Z, Pows M, Kukreji V, Krzyanowska MK. Development and validation of a score to predict acute care use after initiation of systemic therapy for cancer. JAMA Netw Open 2019;2:e1912823. doi: 10.1001/jama networkopen.2019.12823

Web appendix: Supplementary tables and figures

Web appendix 1: Supplementary file 1—Symptom Management Guide for Early Stage Breast Cancer Patients receiving Adjuvant and Neoadjuvant Chemotherapy, Patient Version

Web appendix 2: Supplementary file 2—AToM telephone follow-up form

Web appendix 3: Supplementary file 3—Symptom Management Guide for Early Stage Breast Cancer Patients receiving Adjuvant and Neoadjuvant Chemotherapy, Provider Version

Web appendix 4: Supplementary file 4—Telephone Script- Follow-Up Calls

Web appendix 5: Supplementary file 5—Details of the Analysis of the Primary Outcome